$AMGN has been discussed by three distinct FinTwit voices across 26 mentions over the past 12 months, with the first mention appearing on September 4, 2025. @jacobplieth has been the most active commentator with 17 mentions, followed by @adamfeuerstein with 9 mentions, and @jasonl_capital with 1 mention. The biotech category has dominated discussion of the stock.

Recent discourse has centered on regulatory and clinical development topics. In late April and early May 2026, @jacobplieth raised questions about accelerated approval rescission and DLL3-targeted therapies, while @adamfeuerstein highlighted FDA initiatives involving $AMGN to accelerate clinical trials using artificial intelligence. The most recent mention occurred on May 8, 2026.